A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

Published:2021-08-13 Issue:10 Volume:116 Page:2014-2025
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Cheifetz Adam S.,Abreu Maria T.,Afif Waqqas,Cross Raymond K.,Dubinsky Marla C.,Loftus Edward V.,Osterman Mark T.,Saroufim Ariana,Siegel Corey A.,Yarur Andres J.,Melmed Gil Y.,Papamichael Konstantinos

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference125 articles.

1. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies;Katsanos;Clin Immunol,2019

2. American Gastroenterological Association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel Diseases;Vande Casteele;Gastroenterology,2017

3. Therapeutic drug monitoring of biologics during induction to prevent primary non-response;Sparrow;J Crohns Colitis,2020

4. How, when, and for whom should we perform therapeutic drug monitoring?;Vermeire;Clin Gastroenterol Hepatol,2020

5. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases;Papamichael;Clin Gastroenterol Hepatol,2019

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucocutaneous manifestations of inflammatory bowel disease;Annales de Dermatologie et de Vénéréologie;2024-09

2. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial;The Lancet Gastroenterology & Hepatology;2024-09

3. Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease;Frontiers in Pharmacology;2024-08-27

4. Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study;Gastroenterología y Hepatología (English Edition);2024-08

5. Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation;The AAPS Journal;2024-07-24